SEATTLE, Feb. 8, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced a poster presentation for its lead product candidate, PRX-OTC, at the 13th Annual WORLDSymposium™ 2017, to be held at the Manchester Grand Hyatt, February 13-17, 2017 in San Diego. PRX-OTC is in development for the treatment of ornithine transcarbamylase deficiency.
- Title of Poster: mRNA Delivery to the Liver Corrects Ornithine Transcarbamylase Deficiency in a Mouse Disease Model
Presenter: Gordon Brandt, M.D.
Time: Tuesday, February 14 from 4:30-6:30 p.m. PST
PhaseRx is a biopharmaceutical company dedicated to developing mRNA products for the treatment of children with inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy (i-ERT). PhaseRx's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of twelve and are characterized by the body's inability to remove ammonia from the blood with potentially devastating consequences for patients. The company's i-ERT approach is enabled by its proprietary Hybrid mRNA Technology™ platform. PhaseRx is headquartered in Seattle. For more information, please visit www.phaserx.com.
Director of Investor Relations
Corporate Communications Contact:
Senior Vice President
Robert H. Uhl
Westwicke Partners, LLC
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/phaserx-to-present-data-for-prx-otc-at-the-13th-annual-worldsymposium-2017-300403968.html
SOURCE PhaseRx, Inc.